nicotinamide-beta-riboside has been researched along with Ototoxicity* in 1 studies
1 other study(ies) available for nicotinamide-beta-riboside and Ototoxicity
| Article | Year |
|---|---|
A reduced form of nicotinamide riboside protects the cochlea against aminoglycoside-induced ototoxicity by SIRT1 activation.
Nicotinamide adenine dinucleotide (NAD. Auditory function and hair-cell (HC) morphology were examined to assess the effects of NRH on kanamycin-induced hearing loss. The pharmacokinetic parameters of NRH were measured in plasma and the cochlea using liquid chromatography tandem mass spectrometry. NAD. NRH alleviated kanamycin-induced HC damage and attenuated hearing loss in mice. NRH reduced gentamicin-induced vestibular HC loss. Compared with NAD and NR, NRH produced more NAD. NRH ameliorates aminoglycoside-induced ototoxicity by inhibiting HC apoptosis by activating SIRT1 and decreasing ROS. NRH is an effective therapeutic option for aminoglycoside-induced ototoxicity. Topics: 14-3-3 Proteins; Aminoglycosides; Animals; Anti-Bacterial Agents; Cochlea; Hearing Loss; Kanamycin; Mice; NAD; Niacinamide; Ototoxicity; Pyridinium Compounds; Reactive Oxygen Species; Resveratrol; Sirtuin 1 | 2022 |